NCT03414814View on ClinicalTrials.gov

Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation

PHASE2CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

January 4, 2018

Primary Completion Date

August 3, 2021

Study Completion Date

August 3, 2021

Conditions

Locally Advanced or Metastatic NSCLC

Interventions

DRUG

Osimertinib 80 MG [Tagrisso]

Osimertinib 80mg once daily until disease progression

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

collaborator

Korean Cancer Study Group

OTHER

lead

Seoul National University Hospital

OTHER